ArticleMolecular biology reports2026
miR-486 attenuates myocardial ischaemia/reperfusion injury by inhibiting apoptosis and autophagy activation via the FOXO1/PTEN/AKT/mTOR axis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEffective therapeutic interventions for myocardial ischaemia/reperfusion injury (MIRI) are lacking. The expression of miR-486, a cardiac-enriched microRNA, is downregulated in ischaemic myocardium; however, its functional role and underlying molecular mechanisms in MIRI remain unclear.
methodsTo overexpress miR-486 in vivo, MIRI rat models were administered miR-486 AAV. Cardiac function was assessed using echocardiography, infarct size using 2,3,5-triphenyltetrazolium chloride staining, and collagen deposition using haematoxylin and eosin and Masson's trichrome staining. In vitro, H9c2 cardiomyocytes were exposed to oxygen-glucose deprivation/reperfusion (OGD/R) and transfected with a miR-486 mimic, miR-486 inhibitor, or respective negative controls. Dual-luciferase reporter assays were conducted in HEK-293T cells to validate FOXO1 and PTEN as direct targets of miR-486. Apoptosis- and autophagy-related protein expression was analysed using western blotting. siRNA-mediated silencing of FOXO1 or PTEN and pharmacological inhibition of AKT (MK2206) or mTOR (rapamycin) were used to establish the underlying signalling axis.
resultsAAV-mediated overexpression of miR-486 significantly improved cardiac function, reduced infarct size, and attenuated myocardial histopathological injury in MIRI rats. In H9c2 cells, the miR-486 mimic suppressed OGD/R-induced elevation of FOXO1 and PTEN protein levels, whereas the miR-486 inhibitor further augmented their expression. MiR-486 directly targeted FOXO1 and PTEN via their respective 3'-UTRs in dual-luciferase reporter assays. MiR-486 overexpression markedly reduced the Bax/Bcl-2 and cleaved caspase-3/caspase-3 ratios. Additionally, it decreased Beclin 1 and LC3-II/GAPDH and increased p62 expression, indicating concurrent suppression of apoptosis and excessive autophagy. Notably, these effects were reversed with miR-486 inhibition. Consistent findings occurred in vivo. siRNA-mediated silencing of either FOXO1 or PTEN partially reversed the pro-apoptotic and pro-autophagic effects induced by miR-486 inhibition. Under OGD/R conditions, the phosphorylation levels of AKT and mTORC1 downstream targets, including S6K and 4EBP1, were restored with miR-486 overexpression. The contribution of AKT/mTOR signalling to the protective effects mediated by the miR-486 mimic was confirmed with AKT or mTOR inhibition.
conclusionsMiR-486 attenuates MIRI by directly targeting FOXO1 and PTEN, thereby facilitating AKT/mTOR pathway activation to co-ordinately suppress cardiomyocyte apoptosis and excessive autophagy. These findings support the involvement of the miR-486/FOXO1/PTEN/AKT/mTOR axis as an important cardioprotective mechanism and identify miR-486 as a potential therapeutic target for MIRI.
Indexed as
Identifiers
42886305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.